These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28901682)

  • 1. Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.
    Rebolj M; Njor S; Lynge E; Preisler S; Ejegod D; Rygaard C; Bonde J
    Cytopathology; 2017 Oct; 28(5):419-428. PubMed ID: 28901682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.
    Rebolj M; Bonde J; Preisler S; Ejegod D; Rygaard C; Lynge E
    PLoS One; 2016; 11(1):e0147326. PubMed ID: 26789267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
    Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
    BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three human papillomavirus DNA assays and one mRNA assay in women with abnormal cytology.
    Rebolj M; Lynge E; Ejegod D; Preisler S; Rygaard C; Bonde J
    Gynecol Oncol; 2014 Dec; 135(3):474-80. PubMed ID: 25449563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
    Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
    BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A daunting challenge: Human Papillomavirus assays and cytology in primary cervical screening of women below age 30years.
    Rebolj M; Bonde J; Ejegod D; Preisler S; Rygaard C; Lynge E
    Eur J Cancer; 2015 Jul; 51(11):1456-66. PubMed ID: 25979832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study.
    Mittal S; Basu P; Muwonge R; Banerjee D; Ghosh I; Sengupta MM; Das P; Dey P; Mandal R; Panda C; Biswas J; Sankaranarayanan R
    Int J Cancer; 2017 Apr; 140(8):1850-1859. PubMed ID: 28108997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
    Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
    J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
    Isidean SD; Wang Y; Mayrand MH; Ratnam S; Coutlée F; Franco EL; Abrahamowicz M;
    Int J Cancer; 2019 May; 144(10):2408-2418. PubMed ID: 30411802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
    Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
    [No Abstract]   [Full Text] [Related]  

  • 20. High-risk HPV detection and associated cervical lesions in a population of French menopausal women.
    Tifaoui N; Maudelonde T; Combecal J; Vallo R; Doutre S; Didelot MN; Nagot N; Segondy M; Boulle N
    J Clin Virol; 2018 Nov; 108():12-18. PubMed ID: 30196012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.